Sign in

What researchers published on Polymyalgia rheumatica

1,081 papers, newest first.

Showing 20 of 1,081

  • Analgesic prescribing in people with polymyalgia rheumatica: a retrospective cohort study in the Clinical Practice Research Datalink.Rheumatology advances in practice
  • Case report[Prednisone-responsive pure red cell aplasia associated with polymyalgia rheumatica].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • Case report[68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT in polymyalgia rheumatica, ovarian teratoma, and reactive peritoneal lesions: a case report.BJR case reports
  • Treatment patterns and outcomes of immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: a single-centre observational study.RMD open
  • Influence of Sex on Glucocorticoid Toxicity Profiles in Polymyalgia Rheumatica.ACR open rheumatology
  • ReviewMore is less: Glucocorticoid-sparing agents in polymyalgia rheumatica.Therapeutic advances in musculoskeletal disease
  • Single-cell transcriptome sequencing analysis of peripheral blood mononuclear cells reveals immune signatures in patients with polymyalgia rheumatica.Frontiers in immunology
  • Case report[A CASE OF POLYMYALGIA RHEUMATICA (PMR)-LIKE irAE DEVELOPING DURING NIVOLUMAB ADMINISTRATION AFTER SURGERY FOR MUSCLE-INVASIVE BLADDER CANCER : A CASE REPORT].Hinyokika kiyo. Acta urologica Japonica
  • ReviewEfficacy and Safety of Janus Kinase Inhibitors in Polymyalgia Rheumatica: A Systematic Review.Cureus
  • International recommendations for the use of imaging in the diagnosis and assessment of polymyalgia rheumatica.Annals of the rheumatic diseases
  • Conversion surgery after atezolizumab plus bevacizumab therapy for postoperative pulmonary metastasis of hepatocellular carcinoma complicated by polymyalgia rheumatica as an immune-related adverse event.Clinical journal of gastroenterology
  • Case reportPostoperative polymyalgia rheumatica after lung cancer resection in the absence of immune checkpoint inhibitors: A case report and literature review.Experimental and therapeutic medicine
  • JAK Inhibitors, Anti-IL-6R Antagonists, Secukinumab, Abatacept, and Rituximab in Polymyalgia Rheumatica: What Insights Emerge from Phase 2 and 3 Randomized Controlled Trials?Medicines (Basel, Switzerland)
  • Frailty characterization and patient-reported outcomes in patients with immune checkpoint inhibitor-related inflammatory arthritis and polymyalgia rheumatica.Rheumatology advances in practice
  • Targeted Therapies in Polymyalgia Rheumatica: From Immunopathophysiology to a Redefined Treatment Paradigm.Drugs
  • Meta-analysisOccurrence and clinical course of immune checkpoint inhibitor-associated inflammatory arthritis and polymyalgia rheumatica-like syndromes: a systematic review and meta-analysis.Frontiers in immunology
  • Beyond disease labels: towards a stratified spectrum model for giant cell arteritis and polymyalgia rheumatica.Rheumatology (Oxford, England)
  • Comment on:18F-fluorodeoxyglucose PET/CT uptake characteristics in ICI-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica.Clinical and experimental rheumatology
  • Therapeutic divergence between polymyalgia rheumatica and giant cell arteritis: lessons from IL-17A inhibition.Clinical and experimental rheumatology
  • GuidelineThe 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica.Rheumatology (Oxford, England)